From Investing.com: 2024-11-19 08:10:35

Bank of America analysts anticipate continued growth for medtech stocks, citing their resilience to healthcare controversies linked to RFK Jr. Recent developments have boosted the sector, narrowing its discount to Tools from 20% to 12% in just two days. Despite trading at a 10% discount, medtech shows potential for further gains due to historical premiums and depressed valuations. While short-term benefits are possible, external factors like tariffs and FX impacts may pose challenges. Nevertheless, growth prospects remain strong, with a focus on quality growth names within the sector. BofA maintains a cautiously optimistic outlook on medtech, highlighting its rebound potential and reduced exposure to healthcare risks.



Read more at Investing.com: Medtech less exposed to potential negative headlines from RFK Jr., says BofA By Investing.com